Chronic Inflammatory Demyelinating Polyneuropathy Incidence in Covid-19 and Covid-19 Vaccines

Authors

  • Simranjit Singh Department of Clinical Medicine, Indiana University School of Medicine, Indianapolis, IN, USA Author
  • Karthik Gangu Department of Internal Medicine, University of Missouri Healthcare, Columbia, USA Author

DOI:

https://doi.org/10.47363/JMHC/2022(4)193

Keywords:

Chronic Inflammatory, Demyelinating, Polyneuropathy Incidence, Covid-19 Vaccines

Abstract

Chronic Inflammatory Demyelinating Polyneuropathy [CIDP] is the most common autoimmune polyneuropathy in adults. CIDP is a demyelinating disease. It is an immune-mediated illness in which the precise mechanism behind the pathophysiology of the immune response is unknown. CIDP is an immune-mediated condition in which both T-cell and humoral mediated immune mechanisms act against myelin components. It is characterized by subacute to chronic onset [> 8 weeks], weakness [both proximal and distal], cyto-albuminologic dissociation [increased CSF protein without pleocytosis], and electrodiagnostic characteristics of asymmetric conduction velocity slowing with features of conduction block [1]. The presence of F-wave latency distinguishes CIDP from other demyelinating neuropathies [2, 3]. Nerve pathology findings of CIDP are segmental demyelination, onion bulb formation, perineural inflammation, and axonal degeneration.

Author Biographies

  • Simranjit Singh, Department of Clinical Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Department of Clinical Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

  • Karthik Gangu, Department of Internal Medicine, University of Missouri Healthcare, Columbia, USA

    Department of Internal Medicine, University of Missouri Healthcare, Columbia, USA

Downloads

Published

2022-06-09